Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Withdrawn 2Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 8Nivolumab 6pembrolizumab 4lenvatinib 3Ipilimumab 3Biopsy 3Axitinib 3vorolanib 2fludarabine 2cabozantinib 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2CTLA-4 Antigen 2toripalimab 1tivozanib 1sodium-iodide symporter 1sintilimab 1pazopanib 1fludarabine phosphate 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1Zoledronic Acid 1Saline Solution 1Rubidium-82 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × tivozanib × Clear all
NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡